Conservative Management of Transitional Cell Carcinoma of
the Kidney and Ureter by Bales, Gregory T. et al.
Diagnosticand Therapeutic Endoscopy, 1995, Vol. 1, pp. 121-123
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1995 Harwood Academic Publishers GmbH
Printed in Malaysia
Conservative Management of Transitional Cell Carcinoma of
the Kidney and Ureter
GREGORY T. BALES, EDWARD S. LYON, and GLENN S. GERBER
Division of Urology, Department ofSurgery, University ofChicago Hospitals and Clinics
(Received November 1, 1993;finalform January 22, 1994)
We report six patients with upper tract transitional cell neoplasms who were treated by an endouro-
logic approach. Two patients had undergone nephroureterectomy previously, whereas one patient
had a single functioning kidney. Two patients were deemed candidates for endourologic procedures
secondary to significant comorbid disease precluding major open surgery. The final patient had a
low-grade distal ureteral lesion and desired a conservative approach.
Of six patients, two were rendered tumor free without recurrence 48 months and 60 months after
surgery. Two patients had multiple superficial recurrences managed endoscopically and are currently
disease free after 12 and 48 months, respectively. One patient died from metastatic transitional cell
cancer 18 months postoperatively whereas one died perioperatively secondary to bleeding and mul-
tiple organ failure.
Of five patients who tolerated endoscopic therapy, four were disease free with a mean follow-up
of 30 months. Endoscopic treatment of upper urinary tract transitional cell carcinoma is feasible, al-
though the risk of disease recurrence and progression may be significant.
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INTRODUCTION
The standard treatment ofupper tract urothelial tumors is
nephroureterectomy with removal ofa cuffofbladder sur-
rounding the ipsilateral ureteral orifice (1-3). However, a
variety of endourological approaches to renal pelvic and
ureteral transitional cell carcinomas have been reported.
Some investigators have suggested that conservative en-
dourologic management in selected patients with upper
tract urothelial tumors and a normal contralateral kidney
may be appropriate (4). In most cases, an endoscopic ap-
proach is selected because oftumor in a solitary renal unit,
bilateral synchronous tumors, renal insufficiency, or sig-
nificantcomorbid disease that precludes a majoropen sur-
gical procedure.We have treated six patients recently with
renal pelvic and/or ureteral malignancy by a variety ofen-
doscopic procedures, and we herein report our results.
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MATERIALS AND METHODS
Six patients with upper tract transitional cell cancer un-
derwent endourologic treatment at the University of
Chicago Hospital using a variety of procedures. Patient
characteristics are presented in Table 1.
Treatmentwas selectedbasedontumorgrade and stage,
radiographic appearance, status of the contralateral renal
unit, and/or presence of significant comorbid disease.
Postoperative surveillance was performed every 3 to 12
months using radiographic and/or endoscopic evaluation.
RESULTS
All patients completed the endourologic procedures suc-
cessfully. The type of treatment performed and the long-
term results are presented in Table 2.
Patient 1 had significant comorbid disease consisting
of diabetes mellitus, severe coronary artery disease, and
cirrhosis. Itwas felt thathe could not tolerate amajoropen
surgical procedure. After an uneventful percutaneous re-
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Table 1 Patient characteristics
Patient Age Presenting Symptoms Intravenous Pyelogram Grade
Findings
Status ofContralatral Kidney
73/M Hematuria
2 84/M Hematuria
3 82/F Hematuria
4 84/M Follow-up pyelogram
5 57/F Hematuria
6 76/F Hematuria
Filling defect, fight II
renal pelvis
Filling defect, right II
renal pelvis
Left UVJ mass with II
hydronephrosis
Filling defect, fight II
distal ureter
Right renal pelvic mass II-III
Filling defect, fight
distal ureter
Nonfunctional
Absent, status post
nephroeureterectomy
Normal
Normal
Absent, status post
nephroureterectomy
Normal
was replaced by a 24F nephrostomy tube. Severe bleed-
ingfromthenephrostomy tractwas encountered. Thiswas
controlled by reinflation of the fascial balloon dilation
catheter within the nephrostomy tract. The patient devel-
oped multiorgan failure and died on postoperative day 2.
Patient 2 had a recurrence at 5 months with a higher
grade lesion (grade IV). This was treated percutaneously,
as was another recurrence 6 months later. The patientdied
18 months after his first procedure from widespread ma-
lignancy.
Patients 3 and 5 had recurrence of superficial transi-
tional cell cancer in the ureter and renal pelvis, respec-
tively, managedby repeat resection at 6-month follow-up.
Both patients have had no further recurrence. Patients 4
and 6 had no further disease after the initial treatment.
There were no complications related to any surgical
procedure other than the death of patient 1.
DISCUSSION
Upper tract transitional cell cancer traditionally has been
managed by nephroureterectomy with removal of a cuffof
bladder. Parenchymal-sparing conservative surgery has
been advocated for selected cases as early as 1948 (5). The
endourologic approach to upper tract urothelial tumors may
beperformedusing ureteroscopyorvia apercutaneous tract.
While several investigators have reported successes with
both these modalities, it is generally preferable to use
ureteroscopy initially and reserve a percutaneous approach
for those tumors that cannot be adequately treated uretero-
scopically. This is largely owing to the risk ofnephrostomy
tract seeding by tumor cells (6). One potential drawback of
an endourologic approach may be the difficulty in ade-
quately staging renal pelvic and ureteral tumors leading to
understaging and inadequate treatment in some cases. In ad-
dition, the risk of local recurrence and disease progression
following endourologic treatment may be significant (7).
Endourologic management ofupper tract tumors in our
series was effective. Five ofthe six patients completed the
procedures successfully.Three ofthese fiveunderwenten-
doscopic treatment of recurrent transitional cell tumors
noted on routine surveillance studies. Three patients are
currently disease free with a fourth having died of unre-
lated causes with no evidence ofdisease. Average follow-
up of these four patients was 42 months.
Therewasone perioperative death in apatient with anon-
functioning contralateral kidney. This patient had severe
Table 2 Treatment results
Patient Treatment Local Recurrence Disease Progression Length ofFollow-up Follow-up Status
Percutaneous Not available Not available Not available Not available
resection
2 Percutaneous 5 months Yes 18 months Metastatic
resection 11 months (died) disease
3 Ureteroscopic 6 months No 12 months Disease free
resection
4 Ureteroscopic No No 60 months Disease free
resection (died)
5 Percutaneous 6 months No 48 months Disease free
resection
6 Ureteroscopic No No 48 months Disease free
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concomitant medical illnesses including diabetes, cirrhosis,
and coronary artery disease precluding a major open surgi-
cal procedure. Significant nephrostomy tract bleeding was
encountered at the end of the procedure, and this ultimately
led to multiorgan failure and death. The second death oc-
curred in an 84-year-old patient with a solitary kidney who
died 18 months after the initial percutaneous resection of a
renal pelvic tumor. In general, tumors ofthe renal pelvis are
largerandmorefrequentlymultifocalthanthoseintheureter.
Therefore, disease progression and local recurrence may be
seen more often afterendourologic treatment ofrenal pelvic
malignancies. Thismaybean importantconsideration in de-
termining treatment options for patients with upper tract
urothelial tumors.
The endourologic approach to transitional cell cancer
of the upper urinary tract in patients with a normal con-
tralateral kidney remains controversial (8,9). While some
authors have advocated this approach in those with low-
stage, low-grade disease, others feel that this is generally
inappropriate. Reasons for this include the risk of local
recurrence and disease progression and the need for fre-
quentendoscopic surveillance postoperatively. In general,
the vast majority of patients with transitional cell cancer
of the upper urinary tract and a normal contralateral kid-
ney should be treated by nephroureterectomy.
In summary, our series supports the feasibility ofan en-
dourologic approach toupperurinary tract transitional cell
cancer. In selected situations such as those involving renal
function, tumor in a solitary kidney, bilateral disease, or
significant comorbid illness, endourologic surgery may
be preferable. However, our series also demonstrates the
significant risk of disease recurrence and progression,
which makes frequent postoperative surveillance manda-
tory. Finally, our single perioperative death is a reminder
that conservative, endourologic procedures still may lead
to significant complications, particularly in elderly pa-
tients with other major medical problems.
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